Phase 2 data for ERLEADA® ▼(apalutamide) plus androgen

Study highlights opportunity for treatment intensification in this population since approximately 50 percent of patients with high-risk localised prostate...

Related Keywords

Texas ,United States ,Belgium ,Beerse ,Region Flamande ,San Antonio ,American ,Henar Hevia ,Luca Dezzani ,Exchange Commission ,Janssen Research Development ,Johnson ,American Urological Association Annual Meeting ,Steering Committee ,Janssen Cilag International ,None Of Janssen Cilag International ,European Medicines Agency ,Janssen Cilag International Nv Inc ,Oral Presentation Session ,Urological Association Annual Meeting ,Steering Committee Chair ,Chief Medical Officer ,Surgical Oncology ,Vice President ,Medical Affairs ,Solid Tumour ,Johnson Innovative ,Senior Director ,Area Lead ,Innovative Medicine ,Cilag International ,Janssen Pharmaceutica ,Janssen Research ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Urological Association Annual ,Cancer Factsheet ,Risk Prostate Cancer ,Very Challenging Disease ,Adjuvant Treatment ,Androgen Deprivation Therapy ,Non Metastatic Prostate Cancer ,Who Are ,High Risk ,Safety Study ,Participants With High Risk ,Radical Prostatectomy ,Janssen Emea ,